Q1 EPS Estimates for Neurocrine Biosciences Cut by Wedbush

Neurocrine Biosciences, Inc. (NASDAQ:NBIXFree Report) – Analysts at Wedbush lowered their Q1 2025 earnings per share (EPS) estimates for shares of Neurocrine Biosciences in a research report issued to clients and investors on Thursday, January 23rd. Wedbush analyst L. Chico now anticipates that the company will post earnings of $1.44 per share for the quarter, down from their prior forecast of $1.52. Wedbush currently has a “Outperform” rating and a $148.00 target price on the stock. The consensus estimate for Neurocrine Biosciences’ current full-year earnings is $3.93 per share. Wedbush also issued estimates for Neurocrine Biosciences’ Q2 2025 earnings at $1.75 EPS, Q3 2025 earnings at $1.85 EPS, Q4 2025 earnings at $2.18 EPS, FY2025 earnings at $7.23 EPS, FY2026 earnings at $9.89 EPS and FY2029 earnings at $21.23 EPS.

A number of other equities analysts have also recently issued reports on NBIX. Barclays upped their price target on shares of Neurocrine Biosciences from $160.00 to $165.00 and gave the stock an “overweight” rating in a research note on Monday, December 23rd. Raymond James reissued an “outperform” rating and set a $155.00 price target on shares of Neurocrine Biosciences in a research report on Thursday, October 10th. Piper Sandler restated an “overweight” rating and issued a $160.00 price objective on shares of Neurocrine Biosciences in a report on Monday, December 23rd. Royal Bank of Canada cut their target price on Neurocrine Biosciences from $136.00 to $133.00 and set a “sector perform” rating on the stock in a research note on Friday, October 4th. Finally, UBS Group upped their price target on Neurocrine Biosciences from $142.00 to $162.00 and gave the company a “buy” rating in a report on Wednesday, January 8th. Five analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $165.40.

Read Our Latest Research Report on Neurocrine Biosciences

Neurocrine Biosciences Trading Up 1.7 %

Neurocrine Biosciences stock opened at $150.71 on Monday. Neurocrine Biosciences has a 12 month low of $110.95 and a 12 month high of $157.98. The company has a market capitalization of $15.26 billion, a price-to-earnings ratio of 40.40 and a beta of 0.33. The business’s fifty day simple moving average is $135.33 and its two-hundred day simple moving average is $131.30.

Insider Transactions at Neurocrine Biosciences

In other Neurocrine Biosciences news, insider Jude Onyia sold 2,331 shares of the stock in a transaction on Friday, November 29th. The stock was sold at an average price of $126.29, for a total value of $294,381.99. Following the completion of the sale, the insider now owns 15,449 shares in the company, valued at approximately $1,951,054.21. This represents a 13.11 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Ingrid Delaet sold 1,091 shares of the business’s stock in a transaction dated Tuesday, December 17th. The shares were sold at an average price of $135.00, for a total value of $147,285.00. Following the completion of the transaction, the insider now owns 2,507 shares in the company, valued at $338,445. The trade was a 30.32 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 68,694 shares of company stock valued at $9,676,730 over the last quarter. 4.30% of the stock is currently owned by company insiders.

Institutional Trading of Neurocrine Biosciences

Several institutional investors and hedge funds have recently added to or reduced their stakes in NBIX. State Street Corp grew its holdings in Neurocrine Biosciences by 11.7% during the 3rd quarter. State Street Corp now owns 5,148,293 shares of the company’s stock valued at $593,186,000 after buying an additional 539,936 shares in the last quarter. Jennison Associates LLC grew its stake in Neurocrine Biosciences by 145.1% during the fourth quarter. Jennison Associates LLC now owns 820,694 shares of the company’s stock valued at $112,025,000 after acquiring an additional 485,894 shares in the last quarter. Los Angeles Capital Management LLC increased its holdings in shares of Neurocrine Biosciences by 639.6% in the third quarter. Los Angeles Capital Management LLC now owns 420,748 shares of the company’s stock worth $48,479,000 after purchasing an additional 363,863 shares during the last quarter. Braidwell LP grew its holdings in Neurocrine Biosciences by 20.9% during the 3rd quarter. Braidwell LP now owns 917,674 shares of the company’s stock valued at $105,734,000 after buying an additional 158,665 shares in the last quarter. Finally, BNP Paribas Financial Markets increased its stake in Neurocrine Biosciences by 23.9% in the 3rd quarter. BNP Paribas Financial Markets now owns 533,324 shares of the company’s stock worth $61,450,000 after acquiring an additional 102,715 shares during the last quarter. Institutional investors own 92.59% of the company’s stock.

About Neurocrine Biosciences

(Get Free Report)

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.

Read More

Earnings History and Estimates for Neurocrine Biosciences (NASDAQ:NBIX)

Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.